Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.
Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age: A Case-Control Study
Meyer Children's Hospital IRCCS
138 participants
Dec 4, 2024
OBSERVATIONAL
Conditions
Summary
This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8 pediatric departments in Tuscany, Italy. First, a matched case-control study investigates the real-world effectiveness of Nirsevimab in preventing RSV-related lower respiratory tract infection (LRTI) hospitalizations during the RSV epidemic season 2024-2025. Second, a descriptive study examines how the Nirsevimab immunization campaign affects RSV epidemiology, focusing on patients' age, comorbidities, infection severity, and clinical outcomes. The findings aim to optimize RSV prevention strategies and inform public health policies.
Eligibility
Inclusion Criteria7
- Case patients
- Age <12 months
- Diagnosis of LRTI (i.e., bronchiolitis and/or pneumonia) at admission
- Positive RSV PCR on nasopharyngeal swab Control patients
- Age <12 months
- Diagnosis of LRTI (i.e., bronchiolitis and/or pneumonia) at admission
- Hospitalized for conditions other than respiratory infections
Exclusion Criteria3
- Parental refusal
- Previous immunization with Palivizumab
- Previous maternal RSV vaccine immunization during pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Evaluation of drug exposure in cases and controls
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06856967